BRPI0416960A - derivado de amina cìclica tendo anel heteroarila - Google Patents

derivado de amina cìclica tendo anel heteroarila

Info

Publication number
BRPI0416960A
BRPI0416960A BRPI0416960-3A BRPI0416960A BRPI0416960A BR PI0416960 A BRPI0416960 A BR PI0416960A BR PI0416960 A BRPI0416960 A BR PI0416960A BR PI0416960 A BRPI0416960 A BR PI0416960A
Authority
BR
Brazil
Prior art keywords
cyclically
heteroaryl ring
amine derivative
represents hydrogen
formula
Prior art date
Application number
BRPI0416960-3A
Other languages
English (en)
Inventor
Tomio Kimura
Atsuhiro Sugidachi
Toshiyuki Konosu
Naoki Tanaka
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BRPI0416960A publication Critical patent/BRPI0416960A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"DERIVADO DE AMINA CìCLICA TENDO ANEL HETEROARILA". Um composto tendo a fórmula geral (I) (em que R¬ 1¬ representa alquila C1-C6, etc., R¬ 2¬ representa hidrogênio, alcanoíla C2-C7, arilcarbonila C7-C11, a fórmula R¬ 4¬ - (CH~ 2~)~ 1~-, etc., R¬ 3¬ representa arila C6-C10, etc., X¬ 1¬, X¬ 2¬, X¬ 3¬, X¬ 4¬ e X¬ 5¬ cada um independentemente representa hidrogênio halogênio, etc. , e n representa um número inteiro de 0 a 2) , sais ou pró-medicamentos farmaceuticamente aceitáveis destes. Eles têm excelente atividade inibitório da ativação plaquetária, etc. e são usados como agentes profiláticos e terapêuticos para doenças relacionadas à formação de trombo ou coágulo.
BRPI0416960-3A 2003-11-28 2004-11-26 derivado de amina cìclica tendo anel heteroarila BRPI0416960A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2003399960 2003-11-28
PCT/JP2004/017974 WO2005051913A1 (ja) 2003-11-28 2004-11-26 ヘテロアリール環を有する環状アミン誘導体

Publications (1)

Publication Number Publication Date
BRPI0416960A true BRPI0416960A (pt) 2007-02-21

Family

ID=34631624

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416960-3A BRPI0416960A (pt) 2003-11-28 2004-11-26 derivado de amina cìclica tendo anel heteroarila

Country Status (15)

Country Link
US (1) US7829580B2 (pt)
EP (1) EP1695962A4 (pt)
KR (1) KR20060108691A (pt)
CN (1) CN1910151A (pt)
AU (1) AU2004293331B2 (pt)
BR (1) BRPI0416960A (pt)
CA (1) CA2547472A1 (pt)
IL (1) IL175614A0 (pt)
MX (1) MXPA06006035A (pt)
NO (1) NO20062988L (pt)
NZ (1) NZ547401A (pt)
RU (1) RU2346935C2 (pt)
TW (1) TW200526624A (pt)
WO (1) WO2005051913A1 (pt)
ZA (1) ZA200604317B (pt)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2547472A1 (en) * 2003-11-28 2005-06-09 Sankyo Company Limited Cyclic amine derivative having heteroaryl ring
US20090306059A1 (en) * 2005-05-13 2009-12-10 Tomio Kimura Cyclic amine derivative having substituted alkyl group
TW200720252A (en) * 2005-05-27 2007-06-01 Sankyo Co Cyclic amine derivative having substituted alkyl group
US9303038B2 (en) 2011-09-06 2016-04-05 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological diseases
JP2015519333A (ja) 2012-05-07 2015-07-09 セリックスビオ プライヴェート リミテッド 神経疾患の治療のための組成物および方法
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
CA2873093A1 (en) 2012-05-07 2013-11-14 Cellixbio Private Limited Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013167991A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
WO2013168022A1 (en) * 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treating atherothrombosis
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
WO2013167992A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of inflammatory disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168001A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2013168016A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of metabolic syndrome
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
US9573927B2 (en) 2012-05-10 2017-02-21 Cellix Bio Private Limited Compositions and methods for the treatment of severe pain
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
WO2013168033A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for treatment of neurologic diseases
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9394288B2 (en) 2012-05-10 2016-07-19 Cellix Bio Private Limited Compositions and methods for the treatment of asthma and allergy
WO2013168005A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
US9315461B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
EP2852570B1 (en) 2012-05-23 2020-04-22 Cellixbio Private Limited Composition for the treatment of inflammatory bowel disease
CN104583182A (zh) 2012-05-23 2015-04-29 塞利克斯比奥私人有限公司 用于治疗粘膜炎的组合物和方法
WO2013175347A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of respiratory disorders
WO2013175376A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of local pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
CN104603097A (zh) 2012-05-23 2015-05-06 塞利克斯比奥私人有限公司 用于治疗多发性硬化症的组合物和方法
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
US9670153B2 (en) 2012-09-08 2017-06-06 Cellix Bio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en) 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
WO2016051420A1 (en) 2014-09-29 2016-04-07 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
SG11201703369WA (en) 2014-10-27 2017-05-30 Cellix Bio Private Ltd Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
DK3242869T3 (da) 2015-01-06 2022-01-31 Cellix Bio Private Ltd Sammensætninger og fremgangsmåder til behanding af inflammation og smerte
CA2997549C (en) * 2015-09-04 2023-10-03 Shin Poong Pharmaceutical Co., Ltd. Compound having effect of inhibiting platelet aggregation and salt thereof, and composition for preventing or treating thrombotic diseases, containing same
CN111763197A (zh) * 2020-07-08 2020-10-13 青岛大学 一种新型手性吲哚类化合物的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0388016U (pt) 1989-12-25 1991-09-09
FI101150B (fi) * 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5750754A (en) 1993-03-29 1998-05-12 Zeneca Limited Heterocyclic compounds
WO1994022835A2 (en) 1993-03-29 1994-10-13 Zeneca Limited Heterocyclic compounds as platelet aggregation inhibitors
NZ334389A (en) 1996-08-28 2001-05-25 Ube Industries Cyclic amine derivatives
JP3274088B2 (ja) * 1996-08-28 2002-04-15 三共株式会社 環状アミン誘導体
JP3907029B2 (ja) 1998-02-27 2007-04-18 三共株式会社 環状アミン誘導体を含有する医薬
KR100567950B1 (ko) 1998-02-27 2006-04-05 상꾜 가부시키가이샤 환상 아미노화합물
JP3856185B2 (ja) * 1998-02-27 2006-12-13 三共株式会社 環状アミノ化合物
CA2446924C (en) 2001-04-19 2011-02-08 Eisai Co., Ltd. 2-iminopyrrolidine derivatives
CA2547472A1 (en) * 2003-11-28 2005-06-09 Sankyo Company Limited Cyclic amine derivative having heteroaryl ring
US20090306059A1 (en) * 2005-05-13 2009-12-10 Tomio Kimura Cyclic amine derivative having substituted alkyl group
JP2007001974A (ja) * 2005-05-27 2007-01-11 Sankyo Co Ltd ヘテロアリール環を有する環状アミン誘導体を含有する医薬組成物

Also Published As

Publication number Publication date
TW200526624A (en) 2005-08-16
EP1695962A4 (en) 2007-03-28
RU2006118326A (ru) 2007-12-10
EP1695962A1 (en) 2006-08-30
MXPA06006035A (es) 2007-01-26
AU2004293331B2 (en) 2008-04-03
US7829580B2 (en) 2010-11-09
CA2547472A1 (en) 2005-06-09
KR20060108691A (ko) 2006-10-18
AU2004293331A1 (en) 2005-06-09
US20060270706A1 (en) 2006-11-30
NO20062988L (no) 2006-08-28
CN1910151A (zh) 2007-02-07
ZA200604317B (en) 2008-01-30
RU2346935C2 (ru) 2009-02-20
NZ547401A (en) 2008-06-30
IL175614A0 (en) 2006-09-05
WO2005051913A1 (ja) 2005-06-09

Similar Documents

Publication Publication Date Title
BRPI0416960A (pt) derivado de amina cìclica tendo anel heteroarila
ATE548031T1 (de) Inhibitoren gegen die produktion und freisetzung entzündungfördernder zytokine
HRP20080113T3 (en) Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
BR0116063A (pt) Inibidores de sulfonamida heterocìclica da produção de beta amilóide e seus usos
HN2002000028A (es) Pirimidinas inhibidoras de metaloproteinasas
ES2193839B1 (es) Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
SE0104140D0 (sv) Novel Compounds
BR0205890A (pt) Pirazolopirimidinas como agentes terapêuticos
NO20021328L (no) Pyrazolopyrimidier som terapeutiske midler
NO20083434L (no) Benzamid- og heteroarenderivater
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
HUP0300616A2 (hu) Adamantánszármazékok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
SE0302811D0 (sv) Novel compounds
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20050088L (no) Kationisk substituerte difenylazefidinoner, fremgangsmate for deres fremstilling, medikamenter inneholdende nevnte forbindelser og anvendelse derav
NO20054135L (no) Kipolinon/benzoksazin derivater og anvendelser derav
BRPI0413094A (pt) derivados de quinolina e seu uso em terapia
BR0210531A (pt) Derivados de ácido sulfÈnico
BR0213464A (pt) Derivados de 3-azabiciclo[3.1.0]hexano como antagonistas receptores de opióide
SE0101932D0 (sv) Pharmaceutical combinations
TR200200100T2 (tr) Kristalin 1-metilkarbapenem türevleri.
UY27685A1 (es) Indolil-urea derivados de tienopiridinas útiles como agentes antiangiogénicos, y procedimientos para su uso
NO20023643D0 (no) Forbindelser som har antitumoraktivitet, fremgangsmåte for deres fremstilling og farmasöytiske sammensetninger som inneholderdem
ME01525B (me) Novi kristalni polimorfni oblici lerkanidipin hidrohlorida i postupak za njihovo dobijanje

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]